Recent IPO Schrödinger (NASDAQ:SDGR) extends its existing collaboration with AstraZeneca (NYSE:AZN)
aimed at enhancing the former’s Free Energy Perturbation technology for
the optimization of key properties of biologics, particularly binding
affinity.
Financial terms are not disclosed.
The physics-based software developer has been one to the top IPOs, still up almost 130% since its debut last month.
Shares ahead 2% premarket on light volume.
https://seekingalpha.com/news/3554121-schrodinger-expands-partnership-astrazeneca
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.